Toward a universal influenza virus vaccine: prospects and challenges.

Current influenza virus vaccines are annually reformulated to elicit protection by generating an immune response toward the virus strains that are predicted to circulate in the upcoming influenza season. These vaccines provide limited protection in cases of antigenic mismatch, when the vaccine and the circulating viral strains differ. The emergence of unexpected pandemic viruses presents an additional challenge to vaccine production. To increase influenza virus preparedness, much work has been dedicated to the development of a universal vaccine. Focusing on regions of viral proteins that are highly conserved across virus subtypes, vaccine strategies involving the matrix 2 protein, stalk domain of the hemagglutinin, and multivalent approaches have provided broad-based protection in animal models and show much promise. This review summarizes the most encouraging advances in the field with a focus on novel vaccine designs that have yielded promising preclinical and clinical data.

[1]  Tao Dong,et al.  Preliminary Assessment of the Efficacy of a T-Cell–Based Influenza Vaccine, MVA-NP+M1, in Humans , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  R. Albrecht,et al.  Influenza Viruses Expressing Chimeric Hemagglutinins: Globular Head and Stalk Domains Derived from Different Subtypes , 2012, Journal of Virology.

[3]  T. Ben-Yedidia,et al.  Safety and Immunogenicity of Multimeric-001—a Novel Universal Influenza Vaccine , 2012, Journal of Clinical Immunology.

[4]  J. Wrammert,et al.  Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses , 2012, Proceedings of the National Academy of Sciences.

[5]  A. Osterhaus,et al.  Induction of Virus-Specific Cytotoxic T Lymphocytes as a Basis for the Development of Broadly Protective Influenza Vaccines , 2011, Journal of biomedicine & biotechnology.

[6]  J. Mascola,et al.  DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials , 2011, The Lancet Infectious Diseases.

[7]  P. Palese,et al.  Why Do Influenza Virus Subtypes Die Out? A Hypothesis , 2011, mBio.

[8]  J. Skehel,et al.  A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins , 2011, Science.

[9]  Martin H. Koldijk,et al.  A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses , 2011, Science.

[10]  W. C. Hwang,et al.  Wide Prevalence of Heterosubtypic Broadly Neutralizing Human Anti–Influenza A Antibodies , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  N. Cox,et al.  Prospecting the influenza hemagglutinin to develop universal vaccines. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  G. Van Domselaar,et al.  Quantitative analyses of all influenza type A viral hemagglutinins and neuraminidases using universal antibodies in simple slot blot assays. , 2011, Journal of visualized experiments : JoVE.

[13]  R. Webby,et al.  Protection against Divergent Influenza H1N1 Virus by a Centralized Influenza Hemagglutinin , 2011, PloS one.

[14]  Ravi S. Misra,et al.  Regulation of Antinucleoprotein IgG by Systemic Vaccination and Its Effect on Influenza Virus Clearance , 2011, Journal of Virology.

[15]  J. Yewdell,et al.  Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection , 2011, The Journal of experimental medicine.

[16]  W. Fiers,et al.  Universal Vaccine Based on Ectodomain of Matrix Protein 2 of Influenza A: Fc Receptors and Alveolar Macrophages Mediate Protection , 2011, The Journal of Immunology.

[17]  A. Hill,et al.  Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA−NP+M1 , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  R. Compans,et al.  Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus , 2010, Proceedings of the National Academy of Sciences.

[19]  D. Ekiert,et al.  Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes , 2010, Proceedings of the National Academy of Sciences.

[20]  Mark R. Soboleski,et al.  Single-Dose Mucosal Immunization with a Candidate Universal Influenza Vaccine Provides Rapid Protection from Virulent H5N1, H3N2 and H1N1 Viruses , 2010, PloS one.

[21]  R. Belshe.  The need for quadrivalent vaccine against seasonal influenza. , 2010, Vaccine.

[22]  G. Nabel,et al.  Induction of Broadly Neutralizing H1N1 Influenza Antibodies by Vaccination , 2010, Science.

[23]  R. Varadarajan,et al.  Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge , 2010, Proceedings of the National Academy of Sciences.

[24]  John Steel,et al.  Influenza Virus Vaccine Based on the Conserved Hemagglutinin Stalk Domain , 2010, mBio.

[25]  R. Belshe,et al.  Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. , 2010, Vaccine.

[26]  R. Hai,et al.  Broadly Protective Monoclonal Antibodies against H3 Influenza Viruses following Sequential Immunization with Different Hemagglutinins , 2010, PLoS pathogens.

[27]  W. Fiers,et al.  M2e-based universal influenza A vaccine. , 2009, Vaccine.

[28]  Gira Bhabha,et al.  Antibody Recognition of a Highly Conserved Influenza Virus Epitope , 2009, Science.

[29]  S. Perk,et al.  A universal epitope-based influenza vaccine and its efficacy against H5N1. , 2009, Vaccine.

[30]  Boguslaw Stec,et al.  Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses , 2009, Nature Structural &Molecular Biology.

[31]  Y. Guan,et al.  Heterosubtypic Neutralizing Monoclonal Antibodies Cross-Protective against H5N1 and H1N1 Recovered from Human IgM+ Memory B Cells , 2008, PloS one.

[32]  J. Sidney,et al.  Immunomic Analysis of the Repertoire of T-Cell Specificities for Influenza A Virus in Humans , 2008, Journal of Virology.

[33]  D. Ho,et al.  A consensus–hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses , 2008, Proceedings of the National Academy of Sciences.

[34]  John Steel,et al.  Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies , 2008, Proceedings of the National Academy of Sciences.

[35]  A Flahault,et al.  Influenza vaccine: the challenge of antigenic drift. , 2007, Vaccine.

[36]  W. Thompson,et al.  Epidemiology of seasonal influenza: use of surveillance data and statistical models to estimate the burden of disease. , 2006, The Journal of infectious diseases.

[37]  K. Matsui,et al.  A fused gene of nucleoprotein (NP) and herpes simplex virus genes (VP22) induces highly protective immunity against different subtypes of influenza virus. , 2006, Virology.

[38]  K. Mozdzanowska,et al.  Prospects for Universal Influenza Virus Vaccine , 2006, Emerging infectious diseases.

[39]  P. Palese,et al.  Making Better Influenza Virus Vaccines? , 2006, Emerging infectious diseases.

[40]  G. Nabel,et al.  Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. , 2005, Vaccine.

[41]  Emily P. Wen,et al.  Universal Influenza B Vaccine Based on the Maturational Cleavage Site of the Hemagglutinin Precursor , 2005, Journal of Virology.

[42]  Keiji Fukuda,et al.  Influenza-associated hospitalizations in the United States. , 2004, JAMA.

[43]  J. Shiver,et al.  Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. , 2004, Vaccine.

[44]  P. Heinen,et al.  Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. , 2002, The Journal of general virology.

[45]  M. Meltzer,et al.  Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. , 2000, JAMA.

[46]  A. Osterhaus,et al.  Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine‐induced antibody response to this strain in the elderly , 2000, Journal of medical virology.

[47]  J. Sidney,et al.  Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism , 1999, Immunogenetics.

[48]  W. Fiers,et al.  A universal influenza A vaccine based on the extracellular domain of the M2 protein , 1999, Nature Medicine.

[49]  T. Ben-Yedidia,et al.  Intranasal administration of peptide vaccine protects human/mouse radiation chimera from influenza infection. , 1999, International immunology.

[50]  K. Mozdzanowska,et al.  Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. , 1999, Virology.

[51]  Y. Isegawa,et al.  The immunological activity of a deletion mutant of influenza virus haemagglutinin lacking the globular region. , 1996, The Journal of general virology.

[52]  B. Bender,et al.  Class I major histocompatibility complex-restricted cytotoxic T lymphocytes are not necessary for heterotypic immunity to influenza. , 1994, The Journal of infectious diseases.

[53]  Y. Isegawa,et al.  A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains , 1993, Journal of virology.

[54]  J. Ulmer,et al.  Heterologous protection against influenza by injection of DNA encoding a viral protein. , 1993, Science.

[55]  Y. Kawaoka,et al.  Location and character of the cellular enzyme that cleaves the hemagglutinin of a virulent avian influenza virus. , 1992, Virology.

[56]  C. Bona,et al.  Influenza A virus transfectants with chimeric hemagglutinins containing epitopes from different subtypes , 1992, Journal of virology.

[57]  R. Lamb,et al.  Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice , 1990, Journal of virology.

[58]  R. Lamb,et al.  Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions , 1988, Journal of virology.

[59]  D. Wraith,et al.  Purified influenza virus nucleoprotein protects mice from lethal infection. , 1987, The Journal of general virology.

[60]  B. Moss,et al.  Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes , 1987, The Journal of experimental medicine.

[61]  A. McMichael,et al.  The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides , 1986, Cell.

[62]  A. McMichael,et al.  Cytotoxic T-cell immunity to influenza. , 1983, The New England journal of medicine.

[63]  R. Elliott,et al.  Evolution of influenza A and B viruses: conservation of structural features in the hemagglutinin genes. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[64]  R. Chanock,et al.  Association of serum anti-neuraminidase antibody with resistance to influenza in man. , 1972, The New England journal of medicine.

[65]  G. Schild,et al.  Related studies of a recombinant influenza-virus vaccine. I. Derivation and characterization of virus and vaccine. , 1971, The Journal of infectious diseases.

[66]  E. D. Kilbourne,et al.  Independent variation in nature of hemagglutinin and neuraminidase antigens of influenza virus: distinctiveness of hemagglutinin antigen of Hong Kong-68 virus. , 1969, Proceedings of the National Academy of Sciences of the United States of America.

[67]  E. D. Kilbourne,et al.  Protective Effects of Specific Immunity to Viral Neuraminidase on Influenza Virus Infection of Mice , 1968, Journal of virology.

[68]  Nicholas S. Kelley,et al.  Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. , 2012, The Lancet. Infectious diseases.

[69]  J. Treanor.  Influenza Viruses, Including Avian Influenza and Swine Influenza , 2010 .

[70]  R. Arnon,et al.  Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection. , 1996, Vaccine.

[71]  R. Lamb,et al.  Orthomyxoviridae: The Viruses and Their Replication. , 1996 .